
Revenue rose 11.6% YoY to Rs 2,708 in Q2FY24. The earnings before interest, tax, depreciation and amortization (EBITDA) grew 15.4% YoY to Rs 686 crore. The EBITDA margin rose 80 basis points YoY to 25.3%.
Domestic branded formulation business increased 7.3% YoY to Rs 253 crore, while consumer healthcare grew only 1.6%.
Mankind attributed the softness in domestic business to delayed acute season. Mankind ranks fourth in the Indian pharmaceutical market with a share of 4.4% in Q2FY24.
Mankind's chronic medicine sales growth was 10% in Q2FY24 as compared to IPM's chronic growth of 9% in Q2FY24. Chronic share increased to 34% in Q2FY24 as compared to 32% in Q2FY23.
Exports business witnessed growth of 159% YoY to Rs 179 crore in Q2FY24 aided by certain one-off opportunities in the US market.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Top Trending Stocks: Sensex Today Live, SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price